Solid Biosciences Inc (B6C.MU)
| Previous close | 1.7186 |
| Open | 1.7196 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 1.7186 - 1.7196 |
| 52-week range | 1.7186 - 25.7790 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 30,949 restricted stock units (“RSUs”) to four newly hired employees. The RSUs vest in four equal installments on each one-year anniversary of the applicable employee’s start date until the fourth anniversary of the applicable employee’s start date. Vesting of t
Simply Wall St.We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- GlobeNewswire
Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results
— Received Rare Pediatric Disease and Orphan Drug Designation for Duchenne musculardystrophy (Duchenne) gene therapy candidate SGT-003 with patient dosing in Phase 1/2 trialexpected Q2 2024 — — Company entered into non-exclusive licensing agreement for use of its proprietary, muscle-targeted AAV-SLB101 capsid — — Company ends first quarter 2024 with approximately $206.1 million in cash and investments.Solid has anticipated cash runway into 2026 — CHARLESTOWN, Mass., May 15, 2024 (GLOBE NEWSWIRE)
